1467060-36-1 Usage
General Description
4-bromo-3,5-difluoro-2-iodoaniline is a chemical compound that belongs to the class of aniline derivatives. It is a substituted aromatic compound with a bromine, fluorine, and iodine atom attached to the benzene ring. 4-bromo-3,5-difluoro-2-iodoaniline has potential applications in pharmaceuticals, agrochemicals, and material sciences due to its unique structure and reactivity. It can be used as an intermediate for the synthesis of various organic compounds, including pharmaceutical drugs and dyes. Additionally, its halogen substituents make it a valuable building block for the development of new materials and specialty chemicals. However, it is important to handle this compound with care as it may pose risks to human health and the environment if not properly managed.
Check Digit Verification of cas no
The CAS Registry Mumber 1467060-36-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,6,7,0,6 and 0 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1467060-36:
(9*1)+(8*4)+(7*6)+(6*7)+(5*0)+(4*6)+(3*0)+(2*3)+(1*6)=161
161 % 10 = 1
So 1467060-36-1 is a valid CAS Registry Number.
1467060-36-1Relevant articles and documents
QUINOXALINE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR
-
Page/Page column 40-41, (2021/07/24)
The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK
-
Paragraph 0809, (2013/10/22)
The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.
